Boston Scientific's SciMed Retains Customers With Interim Pricing Strategy
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's pricing strategy during the first quarter of 1998 helped to preserve its SciMed unit's tenuous interventional cardiology market share position in light of the firm's continued absence from the expanding $1 bil. U.S. coronary stent market.